UNASSIGNED: Between September 2013 and December 2020, a total of 140 patients (56 males, 84 females; mean age: 55.5±10.3 years; range, 32 to 76 years) who underwent minimally invasive Ivor- Lewis esophagectomy for esophageal cancer were retrospectively analyzed. Preoperative patient data, oncological and surgical outcomes, pathological results, and complications were recorded.
UNASSIGNED: Primary diagnosis was esophageal cancer in all cases. Minimally invasive Ivor-Lewis esophagectomy was carried out in all of the cases included in the study. Neoadjuvant chemoradiotherapy was administrated in 97 (69.3%) of the cases. The mean duration of surgery was 261.7±30.6 (range, 195 to 330) min. The mean amount of intraoperative blood loss was 115.1±190.7 (range, 10 to 800) mL. In 60 (42.9%) of the cases, complications occurred in intraoperative and early-late postoperative periods. The anastomotic leak rate was 7.1% and the pulmonary complication rate was 22.1% in postoperative complications. The mean hospital stay length was 10.6±8.4 (range, 5-59) days and hospital mortality rate was 2.1%. The median follow-up duration was 37 (range, 2-74) months and the three- and five-year overall survival rates were 61.8% and 54.6%, respectively.
UNASSIGNED: Minimally invasive Ivor-Lewis esophagectomy can be used safely with low mortality and long-time survival rates in esophageal cancer.
UNASISIGNED:2013年9月至2020年12月期间,共有140名患者(56名男性,84名女性;平均年龄:55.5±10.3岁;范围,对32至76岁)接受微创Ivor-Lewis食管癌切除术的患者进行回顾性分析。术前患者数据,肿瘤和手术结果,病理结果,并记录并发症。
UNASSIGNED:所有病例的主要诊断均为食管癌。在研究中包括的所有病例中都进行了微创Ivor-Lewis食管切除术。97例(69.3%)进行了新辅助放化疗。平均手术时间为261.7±30.6(范围,195至330)分钟。术中平均失血量为115.1±190.7(范围,10~800)mL。在60例(42.9%)中,并发症发生在术中和术后早期至晚期。术后并发症中吻合口漏发生率为7.1%,肺部并发症发生率为22.1%。平均住院时间为10.6±8.4(范围,5-59)天,住院死亡率为2.1%。中位随访时间为37(范围,2-74)个月和3年和5年总生存率分别为61.8%和54.6%,分别。
UNASSIGNED:微创Ivor-Lewis食管癌切除术可安全使用,死亡率低,长期生存率高。